

Freedom of Information (Scotland) Act 2002

Date received	06/09/2022	Subject	metastatic Cholangiocarcinoma (CCA) and Acute myeloid leukaemia (AML)		
Passed to	Acute Services Information Services Pharmacy	Date passed	07/09/2022	Respond by	27/09/2022
Category	Research	FOI number	2022-372		

Question/s to be answered

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.

Shetland patients with the named conditions are treated by NHS Grampian.

Please can I request answers relating to the below questions. A national collation of this information will be made available to any trust requesting it in reply.

1. How many patients in the last 12 months has the trust treated for metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia (AML)?
 - a. For each of AML and CCA, how many have IDH-1 mutation?
 - b. How many CCA are intrahepatic vs extrahepatic?
 - c. How many of each of these present at 2nd line? How many of these at 2nd line have IDH-1 mutation?
 - d. For AML, how many patients were not fit for intensive chemotherapy? How many of these AML patients have IDH-1 mutation?

2. How many patients have been treated with pemigatinib (CCA), venetoclax plus azacitadine dual therapy or azacitadine monotherapy (AML)?
 - a. What is the average treatment duration for CCA patients treated with pemigatinib and AML patients treated with azacitadine dual therapy and azacitadine monotherapy? What is the preferred azacitadine product?

3. What is the real-world dosing for venetoclax (in combination with a CYP3A4)?
 - a. What is the antifungal of choice for patients treated with venetoclax?
 - b. What is the antifungal average treatment duration when used in combination with venetoclax?
 - c. What proportion of patients are treated with an antifungal in combination with venetoclax? In what proportion of patients is the antifungal treatment stopped? In what proportion of these pts is the venetoclax dosage altered following cessation of the antifungal?

Freedom of Information (Scotland) Act 2002

4. Do you routinely test CCA and AML patients for IDH-1 mutation?
 - a. If so when does the testing take place? E.g. at diagnosis or following 1st line progression? Is this done using NGS panel? Is this done using PCR testing?
 - b. What is the average turnaround time for these tests?
5. Who is responsible for the routine management of patients with CCA and AML?
 - a. Clinical oncologist / medical oncologist / specialist nurse etc?
6. How many admissions have occurred in the last 12 months for patients with CCA and AML?
 - a. What is their average length of stay?
 - b. How many of these patients were readmissions or readmitted during this time? If readmitted, can you state the main reason?